Company Overview and News

7
Vijay Mallya diverted Rs 3,700 cr bank loan funds to F1, IPL and for pvt jet sorties: ED chargesheet

2018-06-18 moneycontrol
The Enforcement Directorate today charged embattled liquor baron Vijay Mallya and his two firms for fraudulently "diverting" over Rs 3,700 crore bank loan funds to a UK-based F1 motorsport firm, a T20 IPL team, and for enjoying private jet sorties. The ED's fresh chargesheet against Mallya and his firms is likely to pave the way for him to be declared "fugitive" under a new Indian law.
DB UBL UBHOLDINGS 507458 UNBWY 532478 SBAZ

12
Market Update: Nifty pharma continues to rally as Dr Reddy#39;s jumps 3%; RIL hits record high

2018-06-15 moneycontrol
The broader indices are trading on a flat to positive note this Friday morning with the Nifty up 19 points at 10,822 and the Sensex is up 47 points at 35,647.
500325 UBL RELIANCE IDKQY UBHOLDINGS TCHQY TTNQY 532755 UNBWY 532478 TECHM 535789 IBULHSGFIN 532540 BAJFINANCE INOXWIND RIGD BJJQY TCS 507458 539083 500034 RLNIY

23
Market Update: Bank Nifty in red as Axis Bank, BoB shed 2%; DRL jumps 4%, Jubilant Food at fresh 52-week high

2018-06-15 moneycontrol
The broader indices are trading on a negative note this Friday afternoon with the Nifty down 26 points at 10,781 and the Sensex is trading lower by 94 points at 35,505.
500408 500325 500469 UBL RELIANCE TCHQY FEDA 532755 TTNQY 532215 532478 532540 AXISBANK INOXWIND RIGD FEDS BJJQY FEDERALBNK RLNIY 500034 SBAZ YESBANK AXB UBHOLDINGS FDBAY 532648 YYBKY UNBWY TECHM AXBKY AXBA BAJFINANCE TATAELXSI TCS 539083 507458

18
Carlsberg is said to plan IPO for India operations

2018-06-13 livemint
Hong Kong/Mumbai: Carlsberg A/S is planning a local initial public offering (IPO) of its Indian business, people with knowledge of the matter said, as it seeks to tap the growing middle class’s increasing thirst for foreign beer.
BUD UBL UNITDSPR UBHOLDINGS UNBWY 532478 532432 UQNTY AHBIF DGE 507458 DGE DEO

16
Carlsberg is said to plan local listing for Indian operations

2018-06-13 theedgemarkets
HONG KONG (June 13): Carlsberg A/S is planning a local initial public offering of its Indian business, people with knowledge of the matter said, as it seeks to tap the growing middle class’s increasing thirst for foreign beer.
BUD UBL UBHOLDINGS AHBIF 507458 UNBWY 532478

2
United Breweries Limited - Updates

2018-06-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UBL UBHOLDINGS 507458 UNBWY 532478

2
United Breweries Limited - Updates

2018-06-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UBL UBHOLDINGS 507458 UNBWY 532478

2
'Game-changer': Melbourne to build nation's largest contemporary art gallery

2018-06-02 smh.com.au
Melbourne is set to become home to a Australia’s largest contemporary art gallery as part of a major transformation of the Southbank arts precinct.
UBL UBHOLDINGS 507458 UNBWY 532478

2
United Breweries hits record high on Q4 results

2018-05-25 thehindubusinessline
Shares of United Breweries jumped to a record high on strong Q4 results. The stock jumped as much as 7.6 per cent to a record high of Rs 1,570. The beer brewer's stock posted biggest intraday percentage gain since February 5.
UBL GAILY UBHOLDINGS GAILF 507458 UNBWY 532478

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

1h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...